Rationale: Endothelial progenitor cells (EPCs, defined as sca-1 ؉ flk-1 ؉ linmononuclear blood cells) contribute to vascular repair. The role of hypoxia and reactive oxygen species (ROS) in mobilization and function of these cells is incompletely understood. Objective: We studied the contribution of the NADPH oxidase Nox2, an important vascular source of ROS in this context. Methods and Results: Hypoxia (10% oxygen) induced the mobilization of EPCs in wild-type (WT) and Nox1 but not in Nox2 knockout (Nox2 y/؊ ) mice. As erythropoietin (EPO) is known to induce EPC mobilization, we focused on this hormone. EPO induced the mobilization of EPCs in WT and Nox1 y/؊ but not Nox2 y/؊ animals. Transplantation of bone marrow from Nox2 y/؊ mice into WT-mice blocked mobilization in response to hypoxia and EPO, whereas transplantation of WT bone marrow into Nox2 y/؊ mice restored mobilization. Reendothelialization of the injured mouse carotid artery was enhanced by hypoxia as well as by EPO, and this effect was not observed in Nox2 y/؊
L ocal hypoxia is a phenomenon observed in several disease processes. 1 Hypoxia stabilizes the transcription factor Hif-1 and thereby induces and promotes the expression of several genes containing hypoxia responsive elements in their regulatory region: proangiogenic factors like vascular endothelial growth factor (VEGF) or stromal-cell derived factor-1␣ (SDF-1␣, CXCL12), 2 vasoconstrictors like endothelin-1 as well as inflammation-associated genes such as inducible NO synthase 3 and Cox2. Many of these factors promote angiogenesis and wound healing and are thus critical for the response to local hypoxia and injury. 1 The Hif-1 system is also used to measure the systemic oxygen supply and to control the formation of red blood cells. This effect is mediated by the glycoprotein erythropoietin (EPO) which is mainly produced in the kidney and secreted into the blood, from where it reaches the bone marrow and supports the maturation of red blood cells. 4 EPO binds to a cytokine receptor which does not contain an intrinsic kinase domain. Rather, its signal transduction is mediated by JAK2 (Janus kinase) which phosphorylates tyrosine residues and thereby generates SH2 recognition sites at the EPO-receptor. Via these structures, among others, the signal transducer and activator of transcription 5 (STAT5) is recruited and activated. STAT5 subsequently dimerizes, translocates into the nucleus, and induces transcription. 5 Through this signaling pathway, EPO elicits a plethora of effects that are not just restricted to hematopoesis. EPO has strong organ-protective effects in the heart, the brain, and the kidney, it promotes reendothelialization, 6 and induces the mobilization of endothelial progenitor cells (EPCs). 7 EPCs are bone marrow-derived mononuclear cells which are lineage negative and express the surface markers stem cell antigen (sca-1) or CD34 and endothelial markers like the VEGF-receptor 2 (flk-1 in mice). Additionally, EPCs take up low-density lipoprotein and bind lectin. EPCs are known to contribute to vascular repair, although the exact mechanisms of the action of these cells are still under controversial discussion. Most likely EPCs enhance the reparative capacity of the endothelium adjacent to the injury by releasing paracrine factors. 8, 9 Thus, the label EPCs is misleading. An exact denomination of EPC as sca-1ϩ flk-1ϩ, lineage negative monocytic mononuclear cells with vasculogenic potential and reparative capacity might be more appropriate-also to better acknowledge the complex role of these cells in the vasculature. However, as such a term would largely reduce the readability of the manuscript, we refer to these cells as EPCs in the present study.
Before homing to sites of injury, EPCs have to be mobilized from the bone marrow into the peripheral blood, a process which often involves factors locally produced in the injured tissue like SDF-1␣, granulocyte colony stimulating factor, and VEGF. 10 Importantly, many of these factors are also hypoxia-inducible and thus hypoxia can induce the mobilization of EPCs. 11 Hypoxia alters the cellular redox balance, which is also determined by the expression of antioxidative and prooxidative enzymes. EPCs express high levels of the antioxidative manganese superoxide dismutase and catalase, 12 rendering them relatively resistant to oxidative stress. On the other hand, EPCs have been shown to express the NADPH oxidase Nox2 homologue of the NADPH oxidase family. 13 Given the similarities between EPCs and circulating monocytes, which express particular high level of this NADPH oxidase, Nox2 is likely to have an important role also in EPCs. Nox proteins are main sources of reactive oxygen species (ROS), and the Nox family currently consists of 7 members: Nox1-5 and DUOX 1 and 2. Vascular cells predominantly express Nox1, Nox2, and Nox4, and whereas the ROS-production of the first 2 enzymes occurs in an agonist-dependent manner, Nox4 is constitutively active. 14 NADPH oxidases have an important signaling role as they limit the availability of nitric oxide, 15 and as they are involved in agonist-induced signaling of a broad spectrum of factors including VEGF, 16 thrombin, 17 basic fibroblast growth factor, 18 and platelet derived growth factor. 15 On the basis of the strong interplay between hypoxia, the cellular redox environment, and the effect of hypoxia and ROS on the cellular signal transduction, we studied the role of the NADPH oxidase Nox2 for hypoxia-induced EPC mobilization and vascular repair.
Methods
For a detailed material and methods section please the supplemental materials (available online at http://circres.ahajournals.org).
In this study male C57BL/6N mice, Nox2 y/Ϫ (Jackson Laboratories) and previously characterized Nox1 y/Ϫ 19 were used (both genes are located on the X-chromosome). Animals were exposed to normobaric hypoxia (10% oxygen) or repetitive erythropoietin injections or treated with atorvastatin. Carotid artery reendothelialization was studied after electro injury.
Circulating EPCs were identified as lineage negative, flk-1positive, and sca-1-positive cells as determined by FACS analysis with directly conjugated antibodies. ROS formation was determined by Amplex Red assay, which predominantly detects H 2 O 2 .
All values are meanϮSEM.
Results

Nox2 mRNA Is Highly Expressed in EPCs
To identify the NADPH oxidase homologue predominantly expressed in EPCs, real-time RT-PCR was performed. In lineage negative murine EPCs isolated from the blood, Nox2 expression was approximately 250 times higher than that of Nox4 and more than 30 000 times higher than that of Nox1 (supplemental Table I ). FACS analysis for granulocytes excluded that the high expression of Nox2 was a consequence of a potential contamination of the EPCs.
Hypoxia-Induced Vascular Mobilization of EPCs Essentially Involves Nox2
Exposure to hypoxia for 4 days increased the number of circulating EPCs in wild-type (WT) mice. This effect was, however, not observed in Nox2 y/Ϫ mice. Hypoxia-induced mobilization of EPCs in Nox1 y/Ϫ mice was comparable to that of WT mice ( Figure 1A ). To determine whether this was attributable to a cell intrinsic defect or caused by the environment of the stem cell niche, bone marrow transplantation experiments were performed. The hypoxia-induced mobilization of EPCs was not observed in WT mice transplanted with Nox2 y/Ϫ bone marrow but present in irradiated WT mice repopulated with WT bone marrow ( Figure 1B ). To determine whether the phenotype of Nox2 y/Ϫ mice was a consequence of an altered hypoxia-mediated induction of cytokines, serum-levels of SDF-1␣ and EPO were measured. Hypoxia increased the SDF-1␣ plasma concentration, and 
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STAT signal transducer and activator of transcription VEGF vascular endothelial growth factor WT wild type this effect was similar in WT and Nox2 y/Ϫ mice ( Figure 1C ). Unexpectedly, hypoxia-induced elevations of EPO-levels were substantially greater in Nox2 y/Ϫ mice as compared to WT mice ( Figure 1D ). The latter result was also observed on the EPO mRNA level as determined by real-time RT-PCR from the murine kidney (2 Ϫ⌬⌬CT WT normoxia: 1Ϯ.2, WT hypoxia 4.4Ϯ.3, Nox2 y/Ϫ normoxia: 1.4Ϯ0.4, Nox2 y/Ϫ hypoxia: 25Ϯ1.3, nϭ3). The data suggest that the mobilization defect of Nox2 y/Ϫ mice is not a consequence of an altered cytokine production but rather a defect of cytokine-induced signaling in Nox2-deficient bone marrow cells.
The Erythropoietin-Induced Mobilization of EPCs Requires Nox2
The high expression of EPO in Nox2-deficient mice potentially suggests alterations in EPO signaling in these animals. Thus, further analysis was focused on this hormone. Injection of EPO for 3 days was sufficient to induce mobilization of EPCs in WT mice. Accordingly, in mice subjected to 5/6 nephrectomy, a situation of attenuated renal EPO production, not only anemia was present (Hb mg/dL plasma:15.3Ϯ0.3 sham versus 9.3Ϯ2.5 5/6 nephrectomy) but also the number of circulating EPCs was reduced ( Figure 2A ). This observation indicates a role of the endogenous EPO formation for the basal mobilization of EPCs.
In keeping with the response to hypoxia, EPO-induced mobilization of EPCs was not observed in Nox2 y/Ϫ mice, whereas Nox1 y/Ϫ animals responded similarly as WT mice ( Figure 2B ). This observation was reflected by an inverse effect on the number of colony forming units (CFUs) from bone marrow-derived cells: Ex vivo CFU formation after in vivo EPO stimulation was reduced in WT-and Nox1 y/Ϫ mice but remained unaffected in bone marrow obtained from Nox2 y/Ϫ mice ( Figure 2C ). EPO receptor expression in bone marrow cells was identical between WT and Nox2 y/Ϫ cells as determined by Western Blot analysis (data not shown). Moreover, the expression of endothelial NO synthase in the lung and the EPO-stimulated NO formation of cultured lung endothelial cells was similar between WT and Nox2 y/Ϫ mice (data not shown).
To exclude that Nox2, independently of the agonist administered, is required for the mobilization process per se, the effect of atorvastatin was studied. This HMG-CoA reductase inhibitor is known to induce mobilization of EPCs. 20 HMG-CoA reductase inhibitors in general also prevent the activation of Nox2 via an inhibition of Rac1. 21 Importantly, the atorvastatin-induced mobilization of EPCs was similar in WT-and in Nox2 y/Ϫ mice ( Figure 2D ).
Similar to the effects observed with hypoxia-induced mobilization, bone marrow transplant experiments demonstrated that the altered response to EPO is attributable to a stem cell intrinsic effect rather than a modulation of the stem cell niche: EPO-induced EPC mobilization in Nox2 y/Ϫ mice was restored by transplantation of WT bone marrow ( Figure   Figure 1 . Role of Nox2 for hypoxia-induced mobilization of endothelial progenitor cells. A and B, FACS analyses of lineage negative and Sca-1/flk-1-positive cells in the peripheral blood of (A) wild-type (WT), Nox2 y/Ϫ , and Nox1 y/Ϫ mice exposed to hypoxia (10% oxygen for 4 days) or kept under normoxia and (B) WT mice transplanted with bone marrow of WT or Nox2 y/Ϫ mice. C, SDF-1␣ level in the plasma of WT and Nox2 y/Ϫ mice exposed to hypoxia or normoxia. D, Erythropoietin (EPO) level in the plasma of WT and Nox2 y/Ϫ mice exposed to hypoxia or normoxia. MeanϮSEM; nϭ9 mice for each group; *PϽ0.05 hypoxia vs normoxia, #PϽ0.05 WT vs Nox2 y/Ϫ . Figure 2 . Role of Nox2 for erythropoietin-induced mobilization of EPCs. A, FACS analyses of lineage negative and Sca-1/flk-1positive cells in the peripheral blood of mice exposed to solvent, EPO (1000U/kg), 5/6 nephrectomy or sham operation. B, Lineage-negative and Sca-1/flk-1-positive cells measured by FACS in the peripheral blood of wild-type (WT), Nox2 y/Ϫ , and Nox1 y/Ϫ mice exposed to solvent or EPO. C, CFUs in the bone marrow of WT, Nox2 y/Ϫ , and Nox1 y/Ϫ mice exposed to solvent or EPO. D, Lineage-negative and Sca-1/flk-1-positive cells in the peripheral blood of WT and Nox2 y/Ϫ mice treated with atorvastatin or solvent. E and F, FACS analyses of lineage negative and Sca-1/flk-1-positive cells in the peripheral blood of WT mice transplanted with bone marrow of WT or Nox2 y/Ϫ mice (E) and Nox2 y/Ϫ mice transplanted with bone marrow of WT or Nox2 y/Ϫ mice (F) exposed to EPO or solvent. MeanϮSEM; nϭ5 to 9; *PϽ0.05.
2E), whereas transplantation of Nox2 y/Ϫ bone marrow into WT mice blocked the mobilization in response to EPO ( Figure 2F ). These observations suggest that Nox2 is required for EPO signaling in EPCs.
Nox2 Is Required for the Cellular Response of EPCs to EPO
As ROS are the product of the enzymatic reaction catalyzed by Nox2, we determined the effect of EPO on ROS formation. EPO acutely increased the ROS production in EPCs derived from WT mice, whereas no increase of ROS formation was observed in Nox2-deficient EPCs ( Figure 3A) . Importantly, we observed a similar effect in human cells: EPO increased the ROS formation in human EPCs and treatment with Nox2 antisense but not sense oligonucleotides blocked this effect ( Figure 3B ). As Rac1 is required for Nox2-dependent ROS production, we determined whether this GTPase is activated in response to EPO in endothelial cells. GST-pulldown assay revealed that Rac1 is transiently activated in response to EPO with the maximal effect occurring already after 1 minute ( Figure 3C) . ROS, in a limited concentration range, are known to induce cellular proliferation and migration, two processes which are probably also involved in the mobilization of EPCs. EPOinduced proliferation and migration of cultured EPCs from Nox2 y/Ϫ mice were largely impaired compared to WT-EPCs ( Figure 3D and 3E, statistical analysis of proliferation: WT-solvent 100Ϯ6.5%, WT-EPO 131Ϯ14.2%,* Nox2 y/Ϫ solvent 100Ϯ11.1% Nox2 y/Ϫ EPO 93Ϯ8.7%, nϭ6, *PϽ0.05). Similarly, migration of human EPCs in response to EPO was attenuated after transfection with Nox2 antisense oligonucleotides ( Figure 3F ).
EPO-Induced Signaling Depends on Nox2
The downstream signaling of the EPO/EPO-receptor pathway was assayed with a luciferase reporter gene construct containing gamma activated sites (GAS-luc). 22 This GASelement serves as a binding site for STATs which are activated in response to EPO. As a control the source vector without the enhancer element was used. EPO induced the activity of the GAS-luc construct in transfected lung endothelial cells (LECs) from WT mice but not in Nox2 deficient LECs ( Figure 4A ). Accordingly, an electrophoretic mobility shift assay showed that nuclear translocation of STAT5 in response to EPO-stimulation was less pronounced in Nox2 y/Ϫ than in WT-LECs (data not shown). Overexpression of Nox2 in Nox2 y/Ϫ LEC restored the response of these cells to EPO ( Figure 4B ). In line with these findings EPO-induced phosphorylation of STAT5 was impaired in human EPCs after transfection with Nox2 antisense oligonucleotides ( Figure  4C ). Also, in human umbilical vein endothelial cells (HUVECs) overexpressing the EPO-receptor together with the GAS-luc construct, the EPO-induced enhancement of luciferase activity was completely blocked after treatment with Nox2 antisense oligonucleotides ( Figure 4D ). The EPOinduced proliferation of EPCs required the transcription factor STAT5: Antisense oligonucleotides directed against STAT5b prevented the EPO-induced proliferation ( Figure  4E ). These results indicate that Nox2 has a crucial role in the signal transduction of the EPO-receptor toward STAT5.
The Effects of Nox2 in EPO Signaling Are Mediated by SHP-2
As ROS-mediated signal transduction frequently involves a transient inactivation of phosphatases, we speculate that the EPO-mediated STAT phosphorylation only occurs after Nox2-mediated inhibition of the corresponding phosphatase. Thus, the lack of phosphatase inhibition in Nox2-deficient cells could prevent EPO signal propagation. We therefore repeated the GAS-luc reporter gene assays after treating the cells with siRNA directed against the two central phosphatases SHP-1 and SHP-2 to determine whether downregulation of a specific phosphatase restores EPO signaling in Nox2deficient cells. The impairment of EPO-inducible luciferase expression by Nox2 antisense oligonucleotides in HUVECs was indeed prevented by SHP-2 siRNA. This effect was specific for SHP-2, as siRNA suppressing SHP-1 had no effect on luciferase activity ( Figure 5A ). These data suggest that a Nox2-dependent transient inactivation of SHP-2 is required for EPO-induced signaling such as the activation of STATs. Indeed, acute inhibition of SHP-2 with NSC87877 restored normal EPO-induced invasion of bone marrow cells from Nox2 y/Ϫ mice, whereas the compound had no effect on the invasion in cells obtained from WT animals ( Figure 5B ).
Nox2 Is Involved in Hypoxia-Induced Vascular Repair by Bone Marrow-Derived Cells
To determine the physiological relevance of the present observations, we used the carotid artery electric injury model of vascular repair. EPO enhanced the reendothelialization of the injured carotid artery in WT mice. In contrast, in Nox2 y/Ϫ mice EPO-treatment had no effect on vascular repair ( Figure  6A ). These observations were in line with the results obtained with hypoxia: reendothelialization was stimulated by hypoxia in WT but not in Nox2 y/Ϫ mice ( Figure 6B ). Importantly, this effect of EPO appears to be completely dependent on Nox2 in bone marrow-derived cells: transplantation of WT mice with Nox2-deficient bone marrow blocked EPO-induced vascular repair whereas transplantation of WT bone marrow into Nox2 y/Ϫ mice restored normal repair ( Figure 6C and 6D) .
Discussion
In the present study, we investigated the influence of hypoxia on vascular repair and EPC mobilization. We found that both processes depend on the NADPH oxidase Nox2. EPO alone was sufficient to mimic the effects of hypoxia on EPC mobilization and vascular repair. The signal transduction of EPO critically required Nox2, potentially as Nox2-derived ROS transiently inhibited the phosphatase SHP-2.
Injury-induced mobilization of EPCs from the bone marrow involves the local production of hormones such as VEGF and SDF-1␣, and the subsequently formed gradient between the site of injury and the bone marrow is one of the factors required for EPC release. Interestingly, a role for Nox2 in the signaling of VEGF and SDF-1␣ has been observed: the production of VEGF 23 as well as its signaling require Nox2 and explains why angiogenesis in the femoral artery ligation model of NADPH oxidase-deficient mice is attenuated. 24 In addition the release of SDF-1␣ from the injured hindlimb is reduced in Nox2-deficient mice, which results in a reduced mobilization of EPCs in this disease model. 25 Systemic hypoxia differs considerably from the experimental situation of hindlimb ischemia, as a similar drop in oxygen tension occurs in the bone marrow and the other tissues of the body. Moreover, in contrast to the ischemic hindlimb ligation model, 25 the increase in SDF-1␣ induced by systemic hypoxia was not dependent on Nox2, suggesting that a second factor, possibly EPO, accounts for the effects of Nox2 in the present study.
EPO has previously been shown to be a strong stimulus for EPC mobilization in mice and humans. 7, 26 The data of the present study indicate that EPO production is unaffected in Nox2 y/Ϫ mice but that EPO signaling is impaired in these animals. Thus, ROS play a central role in the signaling transduction induced by EPO. It has previously been noted that NO is also involved in EPO-induced mobilization. 27 As there is crosstalk been NO and O 2 -, some interaction between the two systems cannot be excluded. Endothelial NO synthase expression in EPCs, however, is very low and thus probably endothelial cells in the vascular niche of the bone marrow are important targets for EPO-induced NO production and are involved in the release of EPCs. In contrast to this concept, Nox2 signaling, as demonstrated in the present study, rather occurs in bone marrow-derived cells directly.
In the present study we focused on EPO-mediated activation of STATs. These transcription factors are phosphorylated and activated within a cascade of tyrosine phosphorylation events after EPO receptor activation. Termination of the EPO signal involves internalization and dephosphorylation of the receptor and of its downstream targets. 28 Among the large family of tyrosine-phosphatases, several enzymes have been identified to be of relevance for this processes (ie, APC1, also known as low molecular weight phosphatase, isoforms of PTP1B, SHP-1 and SHP-2). 29 Interestingly, the activity of all these phosphatases has been reported to be exquisitely redoxsensitive, 30 which is a consequence of a highly reactive cysteine in the active centers of these enzymes. It is known that low concentrations of H 2 O 2 are able to oxidize this amino acid in a reversible manner. For several receptors such as the EGF and PDGF receptor it has been shown that the transient inhibition of phosphatases is required for the signal transduction. 30 Redox-mediated inhibition of phosphatases is also necessary for the signaling of interleukin-4 receptor, 31 which has some similarity to the EPO receptor. This concept implies that agonists of the above mentioned receptors concomitantly increase the cellular ROS production, what indeed has been shown for all of the above mentioned stimuli. Depending on the cell type and receptor, different Nox homologues have however been identified as the source of agonist-induced ROS formation. 15 In line with this principle, we observed that EPO stimulation of EPCs also increased their ROS formation, and we identified Nox2 as the source of ROS in these cells. Among the NADPH oxidase homologues expressed in EPCs, ROS production by Nox1 and Nox2 requires acute agoniststimulation whereas Nox4 is constitutively active. As EPO acutely increased ROS, a role for Nox4 in this process is not very plausible.
Indeed, ligand binding to the EPO receptor activates all pathways required for Nox2 assembly such as PKC, Vav, and PI3K, which subsequently stimulate p47phox and Rac1, respectively. 28 The activation of Nox1 is similar to that of Nox2 in some aspects. 15 Nevertheless, the data obtained with Nox1 y/Ϫ mice in the present study clearly demonstrate that EPO signaling in EPCs as well as in HUVECs involves Nox2 but not Nox1.
As a main read-out in the present study, we used a STAT5 reporter system and could demonstrate that EPO-induced STAT5 activation was absent after Nox2 depletion. This effect of Nox2 downregulation was prevented by siRNA directed against the phosphatase SHP-2. From this observation we infer that a physiological function of Nox2 is the transient inhibition of SHP-2 to allow EPO signaling. Indeed, inhibition of SHP-2 restored EPO-induced invasion of bone marrow cells. In fact, there is a growing number of studies linking different NADPH oxidases to signal propagation via inhibition of phosphatases: The signaling of the interleukin-4 receptor requires inhibition of PTP1B by Nox1 or Nox5. 31 NADPH oxidase-mediated inhibition of this phosphatase is also involved in EGF receptor signaling. 32 Also, the signaling by VEGF depends on NADPH oxidases, and it has been shown that a Nox2-mediated inhibition of PTP1B is required for the endothelial responses to this growth factor. 16, 24, 33 PTP1B is not the only phosphatase inhibited by NADPH oxidases: inhibition of the low molecular weight phosphatase is involved in insulin-like growth factor 1-mediated activation of JAK2, 34 and recently it has been shown that SHP-2 is oxidized in response to angiotensin II in vascular smooth muscle cells by Nox1-dependent ROS production. 35 Interestingly, although SHP-1 is also redox-sensitive, 36 EPO-induced STAT activation in Nox2-deficient cells was not restored by SHP-1 siRNA. The redox-sensitivity of SHP-1 is determined by the cell type and the local environment, 36 and in macrophages an NADPH oxidase-mediated agonist-dependent inhibition of this phosphatase has indeed been observed. 37 Thus, our data do not exclude inactivation of SHP-1 in Figure 6 . Role of Nox2 in hypoxia-induced vascular repair. Statistical analyses and exemplary scans of the reendothelialization of carotid arteries determined by Evans blue staining 3 days after electric injury in wild-type (WT) and Nox2 y/Ϫ mice. A, Animals were treated with or without EPO for 3 days (1000 U/kg). B, Animals were subjected to hypoxia (10% oxygen) or normoxia for 4 days. nϭ6 to 9; *PϽ0.05. WT (C) and Nox2 y/Ϫ (D) animals were transplanted with bone marrow cells from WT or Nox2 y/Ϫ mice and treated with or without EPO for 3 days (1000 U/kg). nϭ3; *PϽ0.05.
general but suggest that for the present setting and EPO receptor-induced STAT-signaling, SHP-2 is the phosphatase mainly involved.
In the present study, we observed that EPO, in a Nox2dependent manner, promoted vascular repair and induced mobilization of EPCs. Although it is certainly tempting to conclude that alterations within the EPCs directly affect vascular repair (although the mechanism is unclear), it should not be ignored that endothelial cells in situ express the EPO receptor and that treatment with EPO has been shown to directly improve angiogenesis 38 and endothelial function. Interestingly, several of the direct vascular effects of EPO involve endothelial NO production probably as a consequence of EPO-mediated phosphorylation of endothelial NO synthase 39 or potentially even local VEGF production. 40 The data obtained by bone marrow transplant, however, clearly indicate that in addition to this system, Nox2 in bone marrow-derived cells is involved in vascular repair. The data also suggest that, at least in the model of electric-injury, bone marrow-derived cells directly contribute to this process.
In some experiments of the present study we were forced to use endothelial cells rather than EPCs as we failed to transfect EPCs. Our data confirm EPO-induced signaling in lowpassage endothelial cells. Overexpression of the EPO receptor increased EPO-dependent signaling, but the dependency of the signal on Nox2 was not altered by this approach.
In summary, EPO binds to the EPO receptor which then dimerizes and allows binding of JAK2. JAK2 creates SH2 binding sites by phosphorylating tyrosine residues at the receptor. Phosphorylation of the receptor activates Rac1 and PI3K which leads to the assembly of Nox2-containing NADPH oxidase subsequently producing superoxide anions. Superoxide anions are dismuted to H 2 O 2 , which inactivates SHP-2. Meanwhile, STAT5 binds to the SH2 domains of the EPO-receptor, where it gets phosphorylated, dimerizes, and eventually translocates to the nucleus to induce transcription of target genes leading to proliferation, migration, and mobilization. If no ROS are produced by Nox2, SHP-2 is not inactivated and dephosphorylates STAT5 before STAT5mediated signaling can occur (Figure 7) . The consequence of this is that hypoxia-as well as erythropoietin-induced mobilization of EPCs and vascular repair-are absent in Nox2deficient animals.
